Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting

California biotech firm Kamau Therapeutics, co-founded by Stanford physician-scientist Matthew Porteus, has unveiled promising clinical data on its first batch of gene-edited patients suffering from sickle cell disease (SCD). This data, which will be showcased at the upcoming American Society of Hematology (ASH) conference, reveals precise correction of the SCD mutation in the β-globin gene, coupled with the restoration of adult hemoglobin (HbA) expression in three patients.

Unlike FDA-approved Casgevy, which tackles the SCD mutation by altering fetal hemoglobin (HbF) expression, Kamau utilizes a direct replacement of the SCD mutation via homology-directed repair (HDR) of the β-globin gene. Three patients are currently transfusion-independent and have not suffered any pain crises since receiving their gene-edited hematopoietic stem cells (HSCs).

Kamau's Director of Research and Development, Matthew Porteus, expressed optimism about the initial findings, stating that the results met their expectations for HDR to function effectively in engraftable HSCs. He emphasized that they are now actively recruiting additional patients and preparing to discuss the study design with the FDA. The Phase I/II RESTORE trial is enrolling approximately 15 participants, with more data expected to be presented at ASH to bolster the study's safety, efficacy, and sustainability.

Kamau's approach contrasts with Casgevy, which employs an HbF switching strategy. Porteus believes that the HDR method could prove more advantageous in the long run, as it results in a substantially greater reduction of HbS levels compared to HbF approaches. This, in turn, could help prevent the various organ damage issues associated with SCD. Porteus also highlighted the potential long-term benefits of Kamau's method, including better organ health and a more tunable HbA profile under varying oxygen conditions.